{"id":"W2910893459","doi":"10.1158/1078-0432.ccr-18-2435","title":"Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Seattle Genetics; Takeda Oncology; Takeda Pharmaceutical Company","keywords":"Brentuximab vedotin; Medicine; Chemotherapy; Stage (stratigraphy); Oncology; Lymphoma; Internal medicine; Hodgkin lymphoma; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009056855,0.000239758,0.0009360558,0.0002068796,0.0002335403,0.0003912477,0.0001977812,0.0003231332,0.001614214],"category_scores_gemma":[0.000833772,0.0001835495,0.0005137757,0.0002655499,0.0002308296,0.0002693286,0.0001540889,0.0004766549,0.0001988198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004177982,"about_ca_system_score_gemma":0.0005906102,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001259127,"about_ca_topic_score_gemma":0.00407315,"domain_scores_codex":[0.9995784,0.0002640363,0.0000274031,0.00005329193,0.00004208861,0.00003480219],"domain_scores_gemma":[0.9993939,0.0001636222,0.0002045377,0.0000301995,0.00005181257,0.0001558892],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5712258,0.01483159,0.1802617,0.002655277,0.00565111,0.0003209502,0.0004230573,0.000789577,0.01432914,0.0001736357,0.004733631,0.2046045],"study_design_scores_gemma":[0.2005158,0.2802626,0.5006645,0.0003248381,0.00400123,0.0005672965,0.0003411902,0.001170507,0.002114279,0.0002706272,0.009731248,0.0000358244],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930138,0.005509744,0.00007225417,0.000145591,0.00005195475,0.0002032932,0.0002399025,0.00001055008,0.0007528659],"genre_scores_gemma":[0.9967136,0.001773174,0.0001305381,0.000350159,0.00007845775,0.0001563761,0.0002722192,0.000002249977,0.0005231612],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9987409,"threshold_uncertainty_score":0.005400062,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1015717345262196,"score_gpt":0.4519525788486962,"score_spread":0.3503808443224766,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}